ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "LDL, Lp(a), CRP: Independent CV Event Predictors. 10/14/25"
Episode Synopsis
Welcome to Cardiology Today – Recorded October 14, 2025. This episode summarizes 5 key cardiology studies on topics like C.O.V.I.D.-19 and Low-density lipoprotein cholesterol. Key takeaway: LDL, Lp(a), CRP: Independent CV Event Predictors..
Article Links:
Article 1: Accelerated vascular ageing after COVID-19 infection: the CARTESIAN study. (European heart journal)
Article 2: Heparin administration at first medical contact vs immediately before primary percutaneous coronary intervention: the HELP-PCI trial. (European heart journal)
Article 3: Low-density lipoprotein cholesterol, lipoprotein(a) and high-sensitivity C-reactive protein are independent predictors of cardiovascular events. (European heart journal)
Article 4: Low-density lipoprotein cholesterol, C-reactive protein, and lipoprotein(a) universal one-time screening in primary prevention: the EPIC-Norfolk study. (European heart journal)
Article 5: DanGer shock criteria and outcomes in acute myocardial infarction-related cardiogenic shock treated with Impella: the J-PVAD registry. (European heart journal)
Full episode page: https://podcast.explainheart.com/podcast/ldl-lpa-crp-independent-cv-event-predictors-10-14-25/
Featured Articles
Article 1: Accelerated vascular ageing after COVID-19 infection: the CARTESIAN study.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40819656
Summary: The C.A.R.T.E.S.I.A.N. study, a prospective, multicentric cohort investigation across 16 countries, confirmed accelerated vascular aging following C.O.V.I.D.-19 infection. By comparing C.O.V.I.D.-19-negative controls with individuals 6 ± 3 months post-infection, the study established a significant link between the virus and long-term vascular damage. These findings underscore the importance of long-term cardiovascular monitoring in C.O.V.I.D.-19 survivors due to an increased risk of complications.
Article 2: Heparin administration at first medical contact vs immediately before primary percutaneous coronary intervention: the HELP-PCI trial.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40748607
Summary: trial. The H.E.L.P.-P.C.I. trial, an investigator-initiated randomized controlled study, investigated the optimal timing for unfractionated heparin administration in patients with S.T.-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Patients were randomized to receive unfractionated heparin either at first medical contact or immediately before the procedure. The abstract describes the study’s design and rationale, addressing the clinical uncertainty regarding the efficacy of pre-treatment, but the specific trial results or conclusions are not provided within the abstract itself.
Article 3: Low-density lipoprotein cholesterol, lipoprotein(a) and high-sensitivity C-reactive protein are independent predictors of cardiovascular events.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40320753
Summary: This U.K. Biobank analysis of 322,922 participants revealed that low-density lipoprotein cholesterol, lipoprotein(a), and high-sensitivity C-reactive protein are independent predictors of incident major adverse cardiovascular events. The study demonstrated these biomarkers’ associations, both individually and in combination, with cardiovascular outcomes, irrespective of cholesterol-lowering medication status. These findings support the utility of assessing these three markers for robust cardiovascular risk stratification.
Article 4: Low-density lipoprotein cholesterol, C-reactive protein, and lipoprotein(a) universal one-time screening in primary prevention: the EPIC-Norfolk study.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40167249
Summary: The E.P.I.C.-Norfolk study investigated the validity and generalizability of a proposed universal one-time screening strategy for low-density lipoprotein cholesterol, high-sensitivity C-reactive protein, and lipoprotein(a) in primary prevention. This prospective European cohort enrolled 17,087 initially healthy participants, measuring these biomarkers at study entry. The abstract highlights the study’s aim to validate previous findings from an American cohort, but it does not present the specific outcomes or conclusions from the E.P.I.C.-Norfolk analysis itself.
Article 5: DanGer shock criteria and outcomes in acute myocardial infarction-related cardiogenic shock treated with Impella: the J-PVAD registry.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41078250
Summary: registry. The J-P.V.A.D. registry study aimed to evaluate outcomes in acute myocardial infarction-related cardiogenic shock patients treated with Impella, stratified by DanGer shock eligibility criteria. Analyzing 3975 patients from a nationwide Japanese registry, the study sought to understand the real-world distribution and efficacy of Impella use beyond the highly selected DanGer shock trial population. However, the abstract itself does not present the specific findings or comparative outcomes regarding DanGer shock-eligible versus ineligible patient groups.
Transcript
Today’s date is October 14, 2025. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. Accelerated vascular ageing after COVID-19 infection: the CARTESIAN study. The C.A.R.T.E.S.I.A.N. study, a prospective, multicentric cohort investigation across 16 countries, confirmed accelerated vascular aging following C.O.V.I.D.-19 infection. By comparing C.O.V.I.D.-19-negative controls with individuals 6 ± 3 months post-infection, the study established a significant link between the virus and long-term vascular damage. These findings underscore the importance of long-term cardiovascular monitoring in C.O.V.I.D.-19 survivors due to an increased risk of complications.
Article number two. Heparin administration at first medical contact vs immediately before primary percutaneous coronary intervention: the H.E.L.P.-P.C.I. trial. The H.E.L.P.-P.C.I. trial, an investigator-initiated randomized controlled study, investigated the optimal timing for unfractionated heparin administration in patients with S.T.-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Patients were randomized to receive unfractionated heparin either at first medical contact or immediately before the procedure. The abstract describes the study’s design and rationale, addressing the clinical uncertainty regarding the efficacy of pre-treatment, but the specific trial results or conclusions are not provided within the abstract itself.
Article number three. Low-density lipoprotein cholesterol, lipoprotein(a) and high-sensitivity C-reactive protein are independent predictors of cardiovascular events. This U.K. Biobank analysis of 322,922 participants revealed that low-density lipoprotein cholesterol, lipoprotein(a), and high-sensitivity C-reactive protein are independent predictors of incident major adverse cardiovascular events. The study demonstrated these biomarkers’ associations, both individually and in combination, with cardiovascular outcomes, irrespective of cholesterol-lowering medication status. These findings support the utility of assessing these three markers for robust cardiovascular risk stratification.
Article number four. Low-density lipoprotein cholesterol, C-reactive protein, and lipoprotein(a) universal one-time screening in primary prevention: the E.P.I.C.-Norfolk study. The E.P.I.C.-Norfolk study investigated the validity and generalizability of a proposed universal one-time screening strategy for low-density lipoprotein cholesterol, high-sensitivity C-reactive protein, and lipoprotein(a) in primary prevention. This prospective European cohort enrolled 17,087 initially healthy participants, measuring these biomarkers at study entry. The abstract highlights the study’s aim to validate previous findings from an American cohort, but it does not present the specific outcomes or conclusions from the E.P.I.C.-Norfolk analysis itself.
Article number five. DanGer shock criteria and outcomes in acute myocardial infarction-related cardiogenic shock treated with Impella: the J-P.V.A.D. registry. The J-P.V.A.D. registry study aimed to evaluate outcomes in acute myocardial infarction-related cardiogenic shock patients treated with Impella, stratified by DanGer shock eligibility criteria. Analyzing 3975 patients from a nationwide Japanese registry, the study sought to understand the real-world distribution and efficacy of Impella use beyond the highly selected DanGer shock trial population. However, the abstract itself does not present the specific findings or comparative outcomes regarding DanGer shock-eligible versus ineligible patient groups.
Thank you for listening. Don’t forget to subscribe.
Keywords
C.O.V.I.D.-19, Low-density lipoprotein cholesterol, low-density lipoprotein cholesterol, unfractionated heparin, universal screening, first medical contact, post-infection, cardiovascular complications, major adverse cardiovascular events, primary percutaneous coronary intervention, randomized controlled trial, risk prediction, Impella, Acute myocardial infarction, cohort study, lipoprotein(a), vascular aging, Primary prevention, cardiogenic shock, high-sensitivity C-reactive protein, S.T.-elevation myocardial infarction, mechanical circulatory support, DanGer shock.
About
Concise summaries of cardiovascular research for professionals.
Subscribe • Share • FollowThe post LDL, Lp(a), CRP: Independent CV Event Predictors. 10/14/25 first appeared on Cardiology Today.
Article Links:
Article 1: Accelerated vascular ageing after COVID-19 infection: the CARTESIAN study. (European heart journal)
Article 2: Heparin administration at first medical contact vs immediately before primary percutaneous coronary intervention: the HELP-PCI trial. (European heart journal)
Article 3: Low-density lipoprotein cholesterol, lipoprotein(a) and high-sensitivity C-reactive protein are independent predictors of cardiovascular events. (European heart journal)
Article 4: Low-density lipoprotein cholesterol, C-reactive protein, and lipoprotein(a) universal one-time screening in primary prevention: the EPIC-Norfolk study. (European heart journal)
Article 5: DanGer shock criteria and outcomes in acute myocardial infarction-related cardiogenic shock treated with Impella: the J-PVAD registry. (European heart journal)
Full episode page: https://podcast.explainheart.com/podcast/ldl-lpa-crp-independent-cv-event-predictors-10-14-25/
Featured Articles
Article 1: Accelerated vascular ageing after COVID-19 infection: the CARTESIAN study.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40819656
Summary: The C.A.R.T.E.S.I.A.N. study, a prospective, multicentric cohort investigation across 16 countries, confirmed accelerated vascular aging following C.O.V.I.D.-19 infection. By comparing C.O.V.I.D.-19-negative controls with individuals 6 ± 3 months post-infection, the study established a significant link between the virus and long-term vascular damage. These findings underscore the importance of long-term cardiovascular monitoring in C.O.V.I.D.-19 survivors due to an increased risk of complications.
Article 2: Heparin administration at first medical contact vs immediately before primary percutaneous coronary intervention: the HELP-PCI trial.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40748607
Summary: trial. The H.E.L.P.-P.C.I. trial, an investigator-initiated randomized controlled study, investigated the optimal timing for unfractionated heparin administration in patients with S.T.-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Patients were randomized to receive unfractionated heparin either at first medical contact or immediately before the procedure. The abstract describes the study’s design and rationale, addressing the clinical uncertainty regarding the efficacy of pre-treatment, but the specific trial results or conclusions are not provided within the abstract itself.
Article 3: Low-density lipoprotein cholesterol, lipoprotein(a) and high-sensitivity C-reactive protein are independent predictors of cardiovascular events.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40320753
Summary: This U.K. Biobank analysis of 322,922 participants revealed that low-density lipoprotein cholesterol, lipoprotein(a), and high-sensitivity C-reactive protein are independent predictors of incident major adverse cardiovascular events. The study demonstrated these biomarkers’ associations, both individually and in combination, with cardiovascular outcomes, irrespective of cholesterol-lowering medication status. These findings support the utility of assessing these three markers for robust cardiovascular risk stratification.
Article 4: Low-density lipoprotein cholesterol, C-reactive protein, and lipoprotein(a) universal one-time screening in primary prevention: the EPIC-Norfolk study.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40167249
Summary: The E.P.I.C.-Norfolk study investigated the validity and generalizability of a proposed universal one-time screening strategy for low-density lipoprotein cholesterol, high-sensitivity C-reactive protein, and lipoprotein(a) in primary prevention. This prospective European cohort enrolled 17,087 initially healthy participants, measuring these biomarkers at study entry. The abstract highlights the study’s aim to validate previous findings from an American cohort, but it does not present the specific outcomes or conclusions from the E.P.I.C.-Norfolk analysis itself.
Article 5: DanGer shock criteria and outcomes in acute myocardial infarction-related cardiogenic shock treated with Impella: the J-PVAD registry.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41078250
Summary: registry. The J-P.V.A.D. registry study aimed to evaluate outcomes in acute myocardial infarction-related cardiogenic shock patients treated with Impella, stratified by DanGer shock eligibility criteria. Analyzing 3975 patients from a nationwide Japanese registry, the study sought to understand the real-world distribution and efficacy of Impella use beyond the highly selected DanGer shock trial population. However, the abstract itself does not present the specific findings or comparative outcomes regarding DanGer shock-eligible versus ineligible patient groups.
Transcript
Today’s date is October 14, 2025. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. Accelerated vascular ageing after COVID-19 infection: the CARTESIAN study. The C.A.R.T.E.S.I.A.N. study, a prospective, multicentric cohort investigation across 16 countries, confirmed accelerated vascular aging following C.O.V.I.D.-19 infection. By comparing C.O.V.I.D.-19-negative controls with individuals 6 ± 3 months post-infection, the study established a significant link between the virus and long-term vascular damage. These findings underscore the importance of long-term cardiovascular monitoring in C.O.V.I.D.-19 survivors due to an increased risk of complications.
Article number two. Heparin administration at first medical contact vs immediately before primary percutaneous coronary intervention: the H.E.L.P.-P.C.I. trial. The H.E.L.P.-P.C.I. trial, an investigator-initiated randomized controlled study, investigated the optimal timing for unfractionated heparin administration in patients with S.T.-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Patients were randomized to receive unfractionated heparin either at first medical contact or immediately before the procedure. The abstract describes the study’s design and rationale, addressing the clinical uncertainty regarding the efficacy of pre-treatment, but the specific trial results or conclusions are not provided within the abstract itself.
Article number three. Low-density lipoprotein cholesterol, lipoprotein(a) and high-sensitivity C-reactive protein are independent predictors of cardiovascular events. This U.K. Biobank analysis of 322,922 participants revealed that low-density lipoprotein cholesterol, lipoprotein(a), and high-sensitivity C-reactive protein are independent predictors of incident major adverse cardiovascular events. The study demonstrated these biomarkers’ associations, both individually and in combination, with cardiovascular outcomes, irrespective of cholesterol-lowering medication status. These findings support the utility of assessing these three markers for robust cardiovascular risk stratification.
Article number four. Low-density lipoprotein cholesterol, C-reactive protein, and lipoprotein(a) universal one-time screening in primary prevention: the E.P.I.C.-Norfolk study. The E.P.I.C.-Norfolk study investigated the validity and generalizability of a proposed universal one-time screening strategy for low-density lipoprotein cholesterol, high-sensitivity C-reactive protein, and lipoprotein(a) in primary prevention. This prospective European cohort enrolled 17,087 initially healthy participants, measuring these biomarkers at study entry. The abstract highlights the study’s aim to validate previous findings from an American cohort, but it does not present the specific outcomes or conclusions from the E.P.I.C.-Norfolk analysis itself.
Article number five. DanGer shock criteria and outcomes in acute myocardial infarction-related cardiogenic shock treated with Impella: the J-P.V.A.D. registry. The J-P.V.A.D. registry study aimed to evaluate outcomes in acute myocardial infarction-related cardiogenic shock patients treated with Impella, stratified by DanGer shock eligibility criteria. Analyzing 3975 patients from a nationwide Japanese registry, the study sought to understand the real-world distribution and efficacy of Impella use beyond the highly selected DanGer shock trial population. However, the abstract itself does not present the specific findings or comparative outcomes regarding DanGer shock-eligible versus ineligible patient groups.
Thank you for listening. Don’t forget to subscribe.
Keywords
C.O.V.I.D.-19, Low-density lipoprotein cholesterol, low-density lipoprotein cholesterol, unfractionated heparin, universal screening, first medical contact, post-infection, cardiovascular complications, major adverse cardiovascular events, primary percutaneous coronary intervention, randomized controlled trial, risk prediction, Impella, Acute myocardial infarction, cohort study, lipoprotein(a), vascular aging, Primary prevention, cardiogenic shock, high-sensitivity C-reactive protein, S.T.-elevation myocardial infarction, mechanical circulatory support, DanGer shock.
About
Concise summaries of cardiovascular research for professionals.
Subscribe • Share • FollowThe post LDL, Lp(a), CRP: Independent CV Event Predictors. 10/14/25 first appeared on Cardiology Today.
More episodes of the podcast Cardiology Today
CRISPR-Cas9 Gene Editing for Lipids 11/11/25
11/11/2025
In God we trust